miR-221 is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 403-410

  Gordanpour, Aida ^a   Stanimirovic, Aleksandra ^b   Nam, Robert K ^b   Moreno, Carlos S ^c   Sherman, Christopher ^d   Sugar, Linda ^d   Seth, Arun ^a,b,d  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c EMORY UNIVERSITY   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Fusion gene; MicroRNA; Prostate cancer; TMPRSS2:ERG

Indexed keywords

MICRORNA; MIR 221; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DOWN REGULATION; FOLLOW UP; FUSION GENE; GENE EXPRESSION; GENE FUSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENT CANCER; TMPRSS2:ERG; X CHROMOSOME;

ADULT; AGED; COHORT STUDIES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS;

EID: 79953241107     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497-511, 2008.
2. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G and Cooper CS: Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26: 2667-2673, 2007. (Pubitemid 46632014)
3. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R and Chinnaiyan AM: Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188, 2008. (Pubitemid 351240884)
4. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA and Seth A: Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97: 1690-1695, 2007. (Pubitemid 350249347)
5. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE and Gerald WL: TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400-1406, 2009.
6. He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004. (Pubitemid 38868508)
7. Reinhart BJ, Weinstein EG, Rhoades MW, Battel B, and Battel DP: MicroRNAs in plants. Genes Dev 16: 1616-1626, 2002. (Pubitemid 34743323)
8. Chen CZ, Li L, Lodish HF and Battel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86, 2004. (Pubitemid 38055775)
9. Xu P, Vernooy SY, Guo M and Hay BA: The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 13: 790-795, 2003. (Pubitemid 36531030)
10. Bueno MJ, Perez de Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle 7: 3143-3148, 2008.
11. Calin GA and Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394, 2006. (Pubitemid 44289189)
12. Hurst DR, Edmonds MD and Welch DR: Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-7498, 2009.
13. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD and Pollack JR: A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20: 467-473, 2007.
14. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA and Seth A: Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6: 40-45, 2007. (Pubitemid 46294173)
15. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM and Rubin MA: TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341, 2006. (Pubitemid 44449140)
16. Rajput AB, Miller MA, De LA, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME and Huntsman DG: Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60: 1238-1243, 2007. (Pubitemid 350084545)
17. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J and Cooper CS: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263, 2008.
18. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE and Rubin MA: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599, 2007. (Pubitemid 47037039)
19. Narod SA, Seth A and Nam R: Fusion in the ETS gene family and prostate cancer. Br J Cancer 99: 847-851, 2008.
20. Wang J, Cai Y, Ren C and Ittmann M: Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66: 8347-8351, 2006. (Pubitemid 44449142)
21. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W and Pandolfi PP: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624, 2009.
22. Squire JA: TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 41: 509-510, 2009.
23. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
24. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
25. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC and Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
26. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007. (Pubitemid 47037493)
27. Ozen M, Creighton CJ, Ozdemir M and Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793, 2008. (Pubitemid 351380263)
28. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM and Croce CM: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170, 2008.
29. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H and Kneitz B: Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127: 394-403, 2010.
30. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M and Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005. (Pubitemid 41161233)
31. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007. (Pubitemid 46214304)
32. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358, 2005. (Pubitemid 41074723)
33. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM and de la Chapelle A: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080, 2005. (Pubitemid 43049568)
34. Calin GA, Ferracin M, Cimmino A, Di LG, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Ressenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and Croce CM: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005. (Pubitemid 41549891)
35. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De MR, Spagnoli LG, Farace MG and Ciafre SA: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029, 2008.
36. Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsihlias J, Toi A, Ho M, Evans A, Sweet J and Trachtenberg J: Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol 10: 1891-1898, 2003.
37. Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA and Pollak M: Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1270-1273, 2005. (Pubitemid 40656479)
38. Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, Emami M, Sugar L, Sweet J, Toi A and Narod SA: The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 11: 8391-8397, 2005. (Pubitemid 41746952)
39. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Loblaw A, Pond GR, Emami M, Sugar L, Sweet J and Narod SA: Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. Can J Urol 13(Suppl 2): 2-10, 2006.
40. Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A and Narod SA: HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 68: 912-917, 2001. (Pubitemid 32289737)